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1. Introduction 
In the current era, tissue and organ transplantation is an established specialty for treatment 
of multiple disorders. However, the chief immunological problem of organ transplantation 
is the risk of occurrence of acute or chronic rejection, initiated by host lymphocytes in 
response to graft alloantigens. Though the success of transplantation is attributed to the 
modern methods of immunosuppression, the role of pre-transplant blood transfusions 
cannot be ignored.  
Since the beginning of clinical transplantation, there have been four phases in blood 
transfusion policies, swinging from liberal transfusions to avoidance of transfusions, 
followed by a repeat cycle of deliberate transfusions and again returning to abstinence 
(Carpenter, 1990). Pre-exposure to alloantigens has been discovered to have a dual effect: it is 
detrimental in some cases, while in others, it prolongs the graft survival.  
Therefore, in this chapter, we would explore the mechanisms involved in both the 
detrimental and the beneficial effects of blood transfusion on graft survival and provide an 
overview of the current recommended practice.  
2. Basics of HLA and graft rejection 
2.1 Human leukocyte antigens (HLA) are a set of human major histocompatibility complex 
derived glycoproteins. These are expressed on cell surfaces and allow for discrimination of 
self from non-self. HLA have been classified into two major groups, Class I (HLA-A, HLA-B, 
and HLA-C) and Class II (HLA-DP, HLA-DQ, and HLA-DR). Recognition of the 
alloantigens (antigens displayed by the transplanted organ) is the prime event initiating the 
immune response against an allograft (Gabardi, 2010). 
2.2 Hyperacute rejection is an immediate immune response in the recipient against an 
allograft, due to preformed recipient antibodies directed against the donor’s HLA. 
2.3 Acute rejection is a cell mediated process that usually occurs within 5 to 90 days after a 
transplant. Rarely, it can occur after this time.  
www.intechopen.com
 
Blood Transfusion in Clinical Practice 
 
246 
2.4 Humoral rejection is characterized by B lymphocytes injuring the allograft through 
immunoglobulin and complement activities.  
2.5 Chronic rejection: Although poorly understood, immunologic processes of chronic 
rejection may result from cell-mediated, humoral, or drug-induced allograft damage. 
3. History of blood transfusion effect in clinical transplantation  
Most patients with end-stage renal disease awaiting renal transplantation, sustained by 
dialysis machines, became profoundly anaemic and benefitted symptomatically from blood 
transfusions. Many required large numbers of blood transfusions, frequently exceeding 20 
units over a period of months. Some even required as many as 50-100 units. Even those, who 
had some residual production of erythropoietin (EPO) by the remnant renal tissue, 
benefitted by transfusion of 2-5 units per year. Thus, the first phase in clinical 
transplantation was the high-volume use of blood to keep the patient's red cell mass in the 
20-25% range (Carpenter, 1990).  
In the second phase in the 1970s, efforts were made to avoid blood exposure. This trend 
began with the realization that blood exposure could be highly immunogenic leading to 
production of anti-HLA antibodies, which precluded transplantation at the time of cross-
match (Opelz, 1973). This concept was originally described in the mouse by Medawar 
(Medawar, 1946). Subsequently, Hattler et al demonstrated that a single transfusion of whole 
blood can provoke sufficient immune response to induce accelerated rejection of a skin graft 
from the blood donor (Hattler, 1966). This policy of with-holding pre-transplant transfusions 
was reinforced by growing concerns about the serious long-term consequences of 
transfusion-induced hepatitis in the immunosuppressed graft recipient (Parfrey, 1984).  
However, within a few years, it was reported that non-transfused patients receiving 
cadaveric donor grafts were at higher risk for graft rejection, having a 20-30% lower one-
year graft survival rate (Matas 1975, Opelz 1978). In the pre-cyclosporine era, failure to 
transfuse a potential kidney recipient was the most important predictor of a poor outcome. 
It was shown that patients who had never received transfusions were not the optimal 
recipient population (Opelz 1974). Patients who had received blood transfusions prior to 
transplantation appeared to accept a significantly higher proportion of kidney transplants 
successfully (Opelz 1976, Polesky 1976). A similar trend in recipients of heart allografts was 
also noted (Caves 1973). 
Thus, kidney transplant candidates received elective immunomodulatory red cell 
transfusions to improve graft survival. Survival of kidney graft from living related donors 
was enhanced by the pre-transplant conditioning of the recipient with several transfusions. 
However, the volume and timing of blood transfusion which was beneficial, was not 
established. This led to many attempts to define the optimal dose and timing for the 
transfusion effect. Opelz et al found a distinct dose effect, with the one-year survival rates 
being directly proportional to the numbers of units of blood transfused prior to 
transplantation (Opelz 1978). Some improvement was seen with a single transfusion, and 
survival rates increased with up to 10-20 units of blood. However, more recent studies have 
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Though the duration of the favourable effect of blood transfusion was unknown, it was 
found that preoperative blood transfusion at the time of surgery was usually not effective, 
while blood received within a year or two had a beneficial effect (Opelz 1981a). Thus, it was 
recommended that blood should be given at least 3 to 6 months prior to transplant (Radley 
1986). 
It was also not clear which component of the transfused blood was responsible for the 
beneficial effect. Allogeneic blood containing leukocytes was shown to have an adverse 
effect in patients with aplastic anaemia undergoing bone marrow transplantation and in 
renal transplant patients. It was assumed that sensitisation to transplantation antigens could 
potentially be prevented by leukodepleting blood components that are to be used in 
pretransplantation transfusions. Thus, leukocyte poor red cells and frozen deglycerolized 
red cells were assumed to have low incidence of HLA immunization (Sanfilippo 1985, Polesky 
1977).  
The incidence of alloimmunization was also low when stored units, rather fresh units of 
blood were used for transfusion (Light 1982). One study suggested that the agglomeration 
method for blood preservation resulted in a product which was less immunogenic in terms 
of producing antibodies, while retaining its ability to improve graft results (Fuller 1978). 
Thus, preparations of frozen blood deglycerolized by agglomeration were found to be 
beneficial and relatively free of the hazards inherent in conventional blood support. While 
saline-washed, "leukocyte-poor" blood cells may be an alternative to frozen blood for 
reducing the rate of patient sensitization (Miller 1975), prolonged use of this apparently 
leads to a much higher sensitization incidence (Suarez-Ch 1972).  
Thus, numerous studies indicated that blood transfusions may actually be beneficial in 
prolonging the survival of renal allografts (Festenstein 1976, Opelz 1976, Polesky 1976). As a 
result of these data, most transfusion services followed a deliberate transfusion policy of 
administering 2-5 units of blood to all new dialysis patients while awaiting transplantation. 
These were usually given in the form of whole blood, however red blood cells, 
deglycerilized RBC's and buffy coats were also used as effective alternatives to whole blood. 
With the introduction of cyclosporine in 1980s, graft and patient survival improved. Since 
then, the question of the beneficial role of blood transfusions has been subject to ongoing re-
evaluation. There has been an overall decline in the transfusion effect and an increase in the 
HLA matching effect, which is more clearly recognized now because of improved typing 
capabilities. The HLA effect is additive to that of cyclosporine, which itself produces a 15% 
increase in one year survival rates (Opelz 1985). 
In addition, blood transfusion involves a risk of blood-borne infections, including HIV. Also, 
there has been an emergence of new factors in blood banking (e.g. use of EPO for 
supporting red cell production). These formed clear incentives to move away from use of 
pre-transplantation blood transfusions. This led to the fourth phase of transfusion policy, a 
return to the withholding of blood as possibly unnecessary, at least for the improvement of 
graft survival. 
Some recent studies show that transfusion may cause severe acute rejection (Waanders 2008). 
Few programmes now use elective pre-transplant transfusions to improve graft survival. 
Patients with end stage liver diseases are being treated by drug octreotide, variceal banding, 
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sclerotherapy, transjugular intrahepatic portosystemic shunt placements to relieve the 
effects of portal hypertension in order to have less gastrointestinal bleeding and to avoid 
transfusion (Calcutti 2002). 
However, observations on patients having rejection episodes indicate that a beneficial blood 
transfusion effect still exists. Recent evidence suggests that the blood transfusion effect 
remains in certain circumstances, when one considers effects of HLA antigens, rejection 
episodes, and possibly the prospects of tolerance induction. In a single centre study of a no-
transfusion policy, the non-transfused group had more early rejection episodes (Lundgren 
1986). Another study on the relation of rejection activity to previous blood transfusions 
showed that 63% of the 231 non-transfused recipients had rejection episodes during the first 
60 days after transplantation, while 48% of the transfused patients had rejection (Toyotome 
1987). Additionally, it was found that if a rejection episode occurred, the one-year survival 
was 49% in those with no transfusions, and 70% in the transfused patients. Hence, the 
original deficit of 20% poorer survival in the absence of prior transfusions may still be 
discerned in those patients destined to reject. 
Furthermore, though the change in the transfusion effect during the early 1980s (before the 
introduction of cyclosporine) is most marked by a disappearance of the graded response to 
increasing numbers of blood units, the deleterious effect of receiving no transfusions 
remains, with a 10% lower one-year survival rate (Terasaki 1986).  
Unfortunately, there are no reliable predictive tests to know who would need to have 
transfusions prior to transplantation. 
4. Possible mechanism of beneficial effects of pre-transplant transfusion 
The exact mechanism by which blood transfusion enhances transplant survival remains 
unknown. However, several possible mechanisms have been postulated. These are as 
follows: 
4.1 Pre-transplant blood transfusions may cause early immunization of some recipients to 
selected HLA antigens. This enables the pre-transplantation crossmatch to detect those cases 
where rejection of donor organ would be most likely to occur. Preformed HLA antibodies 
(presenting as incompatible crossmatch) are a major contraindication to transplantation. 
About 30% of cases who receive pre-transplant transfusions become highly immunized to 
HLA. This response may be beneficial by preventing an unsuccessful transplant. 
4.2 The beneficial effect of transfusion may also be related to the immunosuppression 
induced by transfusion. This may occur through enhancement of suppressor T cell activity 
or induction of immune tolerance by some unknown mechanism. 
5. Responses to allogenic blood transfusion and HLA senitization 
There are several individual differences in the effects of allogenic blood exposure. Some of 
these are discussed here: 
5.1 Most patients do not develop anti-HLA antibodies following transfusion. Overall, 30% of 
transfused individuals develop antibodies (with the rate being higher in previously 
pregnant females and lower in males) (Opelz 1981b). In non transfused multiparous females, 
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about 10% develop such antibodies (the response being transient usually). Multiparous 
women challenged with blood transfusions show an increase in the responder rate to 30-
40% (Opelz 1981b).  
5.2 Some responders have a highly selective immune response directed to one to four HLA 
antigens, while others show sensitivity to better than 95% of a reference panel (Carpenter 
1990).  
Thus, even though a genetic control over responsiveness is evident, the responder status 
cannot be predicted from an individual's HLA phenotype. 
The responder status to blood transfusions becomes evident very early after the initiation of 
blood transfusions. In the earlier days of frequent transfusions, many patients remained 
negative on antibody screens after more than 50 blood transfusions, and very few non-
responders were found to convert after about six months.  
The degree of sensitization is expressed as panel-reactive antibody (PRA). PRA testing 
evaluates who is most at risk of hyperacute or humoral rejection (Cecka 2010). A PRA of 80% 
reflects that the patient is crossmatch incompatible with 80% of donors. In general, patients 
with a PRA of more than 10% or more than 80% are considered sensitized or highly 
sensitized, respectively. However, different centres can use markedly different PRA cut-offs 
for determining sensitized and highly sensitized patients (Cecka 2010). On a typical waiting 
list for cadaveric renal transplantation, more than 50% of patients have antibodies to more 
than half of the reference panel, and 20% have antibodies to 90-100% (Carpenter 1990). 
There are three types of assays used to determine PRA. The oldest is the Complement 
Dependent Cytotoxicity (CDC) test (Cecka 2010, Hajeer 2006). In this test, patient serum is 
tested against donor lymphocytes (B and T cells). Patients’ antibodies will coat antigen 
expressing lymphocytes and upon administration of complement to the serum, lymphocytes 
are killed and detected by cell stain. The second type of assay is the Enzyme-Linked 
Immunoabsorbant Assay (ELISA), a solid phase assay which is more sensitive than the 
CDC. The third assay is the flow cytometry test. Also, there is the house method where 
locally acquired whole lymphocytes are used and a microbead method which uses purified 
HLA antigen coated microbeads. Commerical kits include the Flow PRA and Luminex tests. 
The CDC is thought to be inferior to the HLA Class I and II ELISA and microbead flow 
cytometry tests which are similar to each other (Cecka 2010, Hajeer 2006, Worthington 2001). 
Though the superiority of one approach over another is debatable, it is important since PRA 
may be altered in response to stimuli. PRA response may be altered by the use of 
medications (rituximab, immune globulin, statins, cyclophosphamide/predisolone with 
plasmapheresis) or certain Angiotensin Converting Enzyme genotypes (Vieira 2004, Vo 2008, 
Muhmoud 2007, Nurhan-Ozdemir 2004, Akcay 2004).  
As previously stated, patients with antibodies to a given donor are not suitable for that 
transplant. Thus, blood transfusions provide a process of negative selection such that 
transplants destined to early failure are avoided. However, immunosuppressive agents such 
as cyclosporine, anti-lymphocyte globulins (ALG), etc, may suppress the responses 
previously subject to negative selection by transfusion, and thus lead to a decline in the 
transfusion effect. Other factors, such as prompt diagnosis and treatment of early rejections 
and HLA matching, may also play a role in this decline observed in the transfusion effect.  
www.intechopen.com
 
Blood Transfusion in Clinical Practice 
 
250 
Iwaki et al demonstrated a benefit from transfusions in HLA-DR mismatched cases. This 
benefit was not observed when there were no mismatches. In cases with no mismatches, 
one-year survival was reported as 80% in both transfused and non-transfused recipients, 
while transfusions added an 8-10% benefit in the one- and two-DR mismatched groups 
(Iwaki 1990). 
6. Nonspecific Immune suppression after transfusion 
Allogeneic blood transfusions produce generalized immunosuppression in the recipient. 
This is due to a variety of changes in the immunological functions, such as decreased 
function of natural killer cells, macrophage migration to sites of injury, lymphocyte 
proliferation, and cutaneous delayed hypersensitivity. Donor leukocytes in allogeneic blood 
may play a role in suppressing cellular immune function. 
Serial measurements of cell-mediated responses in previously non-transfused end-stage 
renal disease patients showed marked reductions in response to mitogens and recall 
antigens (e.g. PPD, tetanus, mumps, vaccinia) after a single blood transfusion. This effect 
lasted for over two weeks (Fischer 1980). More profound and lasting depression was seen 
after a second transfusion given after 4 weeks. 
Reports have also suggested that allogeneic blood transfusions increase the incidence of 
postoperative infection and the tumour recurrence rate (Schriemer 1988, Wu 1988). Such 
postoperative morbidities have been attributed to the immunomodulatory effects of blood 
transfusion. However, this association is unproven, and there is currently insufficient 
evidence to recommend the routine use of leukodepleted blood components for surgical 
patients to prevent either postoperative infection or tumour recurrence. 
7. Antigen specific immune-suppression 
The final objective in transplantation is the induction of specific unresponsiveness, or 
tolerance, so that patients do not need to take anti-rejection medications indefinitely. This 
unresponsiveness is specific for donor antigens; i.e. the recipients produce perfectly normal 
responses to cells bearing other HLA antigens. 
Patients, who have received pre-transplant transfusions, have marked reductions in cells 
capable of killing donor cells (Herzog 1987). However, full activation by polyclonal mitogens 
will restore the expected cytotoxic T cells precursor frequency to the normal level (Dallman 
1989). Thus, the possibility of clonal deletion is unlikely. Though the full T-cell repertoire is 
present, the individual is functionally unresponsive in the absence of stimuli which bypass 
inhibitory immunoregulatory influences. 
When living donor kidney graft recipients are prepared by single-donor blood transfusions 
from the potential kidney donor, this is known as “donor-specific transfusions” (DST). Such 
blood transfusions (which share an HLA haplotype, or at least one DR antigen with the 
transfused recipient) do not produce an increase in cytotoxic T cells precursor frequency or 
cell mediated immunity. If such recipients do not develop a positive cross-match, they are 
still reported to have superior graft survival, close to that of an HLA identical donor 
(Salvatierra 1980).  
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8. Effect of in-utero (feto-maternal) transfusion in adult renal transplant 
Many people behave as if they were clonally deleted for the HLA antigens of their mothers 
which they did not inherit. This was first observed in an analysis of end-stage renal disease 
patients having very high PRA, but consistently having no antibodies against a small 
number of HLA antigens (Claas 1988). This unresponsiveness to antibody response in some 
sensitized patients was found to be due to a failure to respond to non-inherited maternal 
HLA antigens. These findings are important as this may be applicable to selection of donors 
for transplant recipients. 
9. Conditioning with blood transfusions for tolerance induction  
There have been studies reporting selection of single blood donors from an unrelated 
population matched for one DR antigen only and not for a whole HLA haplotype (Lagaaij 
1989). In recipients, anti-HLA antibodies were less frequent as result of one DR matched 
versus no DR matched transfusions. Such transfusions may induce production of anti-
idiotypic antibodies which can prevent the response of T cells specific to the immunizing 
HLA antigens (Phelan 1989, Kawamura 1989).  
Studies of renal and heart transplant recipients have shown a reduced rejection frequency 
and better graft survival when the only blood received prior to transplantation was 1-3 units 
from donors matched for one DR antigen with the recipient (Lagaaij 1989). Anti-HLA 
antibody production was also diminished in the one DR transfused group. This 
immunization effect could be due to suppression via some antigen-specific 
immunoregulatory pathway. 
An alternative possibility could be that provision of self DR on transfused cells induces a 
different sort of systemic response similar to the autologous mixed lymphocyte response 
(AMLR) (Sakane 1979). However, additional confirmatory studies are needed, along with 
careful study of possibly different effects when alloantigens are presented in the context of 
self versus non-self class II HLA.  
10. Conclusions and future research 
Additional adequately powered multi-institutional studies should be conducted, because 
individual centre practices are variable. These studies should have adequate reporting of 
demographics and either use statistical means to account for confounders or use 
randomization. Patients receiving or being randomized to no transfusions should be 
screened to assure that this not only includes transfusions within the dialysis or transplant 
centre, but other transfusions as well.  
The impact of different immunosuppressive regimens on outcomes in patients receiving 
transfusions should be studied to identify those regimens which can suppress the 
advantageous or detrimental effects of transfusion on outcomes. This should be specifically 
evaluated to determine whether transplants need to be encouraged, avoided, or matched 
with certain regimens.  
Unlike the prior reports, where pre-transplant transfusions seemed to worsen renal allograft 
outcomes, transfusions generally have a beneficial to neutral effect on transplant outcomes. 
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There is not much support for the belief that transfusions increase the risk of graft rejection. 
There is evidence that patients receiving pre-transplant transfusions have increased levels of 
sensitization as assessed by PRA. With regard to rejection, the data are more ambiguous with 
some analyses showing benefit, some showing a neutral effect, and other analyses showing 
harm, although the number of studies evaluating more recent time periods is quite limited.  
Thus, future application of deliberate HLA antigen exposure in conjunction with novel 
immunological manipulations may provide a more effective avenue to tolerance induction. 
However, the literature base is weak and future research is needed to assess the impact of 
transfusions on allograft and patient survival outcomes in renal transplant recipients. 
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